Status:
COMPLETED
Comparison of Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Fibromyalgia is a chronic debilitating musculoskeletal pain syndrome. Pregabalin is the only medication that has been approved to treat fibromyalgia in China. Currently, there has been a growing inter...
Eligibility Criteria
Inclusion
- meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for fibromyalgia;
- be between the ages of 18 to 70 years.
Exclusion
- had practiced Ba-Duan-Jin, Tai Chi, yoga or other forms of Qigong exercise within 12 months of their recruitment to the study;
- be less than 40mm of pain VAS score;
- had renal failure, and severe depression or anxiety;
- had any poorly-controlled comorbid medical conditions, such as dementia, cancer, thyroid disease, inflammatory arthritis;
- pregnancy or planned pregnancy within the study period;
- patients residing more than 70 miles from the research site.
Key Trial Info
Start Date :
March 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT03797560
Start Date
March 22 2019
End Date
October 31 2022
Last Update
October 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiao Juan
Beijing, Beijing Municipality, China, 100053